stars 1 stars 2 stars 3

TIRmed Pharma´s product candidate is a chemically stabilized, single-stranded oligonucleotide, which has non-coding and non-complementary sequence. The compound is formulated in a cream aiming for a self-applied and easy to use at-home anti-itch treatment. The product through its mode-of-action, which saves vital immune defenses and has anti-itch effects, would have potential for safe and effective treatment of mild to moderate atopic dermatitis. Atopic dermatitis is associated with a disrupted skin barrier facilitating entry of external allergens and compounds for treatment. Topical delivery to the skin limits systemic adverse events. TIRmed´s cream is intended for early mild-moderate symptoms to limit the use of biologicals.

TIRmed Pharma Questions

The TIRmed Pharma annual revenue was $4 million in 2026.

TIRmed Pharma is based in Stockholm, Stockholm County.

The NAICS codes for TIRmed Pharma are [325, 32].

The SIC codes for TIRmed Pharma are [28, 283].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users